FOR IMMEDIATE RELEASE
JUNE 6, 2019 ANN ARBOR, MI
Genomenon® has released a research report detailing fusion genes of clinical significance found as of April 2019. Fusion genes have long been known to play an important role in the development of cancer. Identifying and documenting each newly discovered fusion is crucial in both patient diagnosis and the development of precision medicines (specifically, targeted therapeutics). The report was compiled using research data found in the Mastermind® Genomic Search Engine.
The Genomenon team used Mastermind to compile a comprehensive knowledgebase of literature describing gene fusions in order to analyze the data and relate the findings in the report. This is the most exhaustive fusion gene knowledgebase in existence, due to the completeness of the Mastermind literature database and the way Mastermind employs Machine Learning (ML) and Artificial Intelligence (AI) to organize and present the data.
The report includes:
The data reveals:
The report is available here: Genomenon Research Report: Fusion Genes of Clinical Significance in 2019
This report was published in cooperation with The Journal of Precision Medicine.
The Mastermind Genomic Search Engine is an evidence-based interpretation tool which provides immediate insight into the full text of millions of genomic articles and supplemental data for every disease, gene, and variant found in the literature. Mastermind is used by hundreds of diagnostic labs around the world to accelerate genomic interpretation, and by pharmaceutical companies to provide a comprehensive genomic landscape for any disease.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
